20 markets identified in PhRMA’s 2018 Special 301 submission are undermining the work of America’s biopharmaceutical innovators. To protect U.S. patents and intellectual property, America must enforce trade agreements and ensure fair access to overseas markets. Special 301 is designed to ensure that our trading partners provide fair access to their markets for IP-intensive U.S. industries.